Prescription medicine
Terazosin Brand names: Tezruly; first approved as Hytrin
Terazosin (Hytrin) is a prescription medicine with an FDA approval on record since 1987. FDA's NDC Directory lists it from 21 generic labelers, and pharmacies paid $0.106 per terazosin 2 mg capsule in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the terazosin FDA label on DailyMed (effective May 5, 2026, Jubilant Cadista Pharmaceuticals Inc.); the NDA 19057 record on Drugs@FDA; every terazosin label on DailyMed.
Highlights of the record
FDA label of May 5, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageTerazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH).
Forms and strengths
- 1 mg
- 2 mg
- 5 mg
- 10 mg
- 1 mg/ml
Capsule; solution.
On the market
- Earliest approval on file
- August 7, 1987 Hytrin, Abbott; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 13 first March 30, 1998; 5 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 22 of which 21 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- February 1, 2041 Tezruly oral solution; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.106 per capsule Terazosin 2 mg capsule
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 2 since 2013 0 Class I among all firms' recalls; latest July 23, 2013; 1 more by firms not listed as its makers
- FAERS reports
- 8,843 through July 30, 2026
What is terazosin used for?
From the label: indications and usageTerazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules. The long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin capsules are also indicated for the treatment of hypertension. Terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.
Conditions named in the indications of terazosin's FDA labels, with every medicine labeled for each:
From other terazosin labelsEnlarged prostate (BPH): INDICATIONS AND USAGE Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH).
FDA pharmacologic class: alpha-Adrenergic Blocker.
Source: FDA drug label (Terazosin), Jubilant Cadista Pharmaceuticals Inc., effective May 5, 2026 (SPL set 43e92495-2cf2-46dd-a80c-f0c3c88c7b73), via openFDA; the full label on DailyMed
Is there a generic for terazosin (Hytrin)?
The FDA approved the first generic terazosin on March 30, 1998. 13 generic applications are approved; 5 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists terazosin from 21 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Hytrin capsules; a patent listed only for Tezruly oral solution runs to February 1, 2041. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1987 earliest approval on file
- 1998 first generic approved
- 2041 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for terazosin (Hytrin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.106 per Terazosin 2 mg capsule, down 13% from $0.121 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Terazosin 2 mg capsule (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Terazosin 1 mg capsule | Generic | $0.108 per capsule | $3.25 | -8% |
| Terazosin 10 mg capsule | Generic | $0.130 per capsule | $3.91 | -11% |
| Terazosin 2 mg capsule | Generic | $0.106 per capsule | $3.17 | -13% |
| Terazosin 5 mg capsule | Generic | $0.108 per capsule | $3.25 | -15% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has terazosin been recalled?
The FDA's Enforcement Report lists 3 recalls naming terazosin since 2013: 0 Class I (the most serious), 3 Class II, 0 Class III; 0 still ongoing. 1 of them is by a firm that FDA's NDC Directory does not list as a maker of terazosin and that holds no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| July 23, 2013 | Class II | Teva Pharmaceuticals USA, Inc. | Labeling -label error on declared strength: unopened, sealed bottle of Terazosin Hydrochloride (HCl) 10mg Capsules contained Terazosin HCl 5 mg Capsules |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: TERAZOSIN HCL, Capsule, 5 mg may have potentially been mislabeled as the following drug: DOXAZOSIN MESYLATE, Tablet, 1 mg, NDC … |
| January 23, 2013 | Class II | Teva Pharmaceuticals USA, Inc. | Presence of Foreign Tablets/Capsules: Recall is being conducted due to a foreign capsule found in one bottle. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the terazosin label say about other medicines?
The terazosin label names 16 other medicines in its interaction, contraindication or warning sections. The labels of 6 other medicines name terazosin. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acetaminophen | drug interactions | Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin); antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); … |
| Allopurinol | drug interactions | … phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); antigout (e.g., allopurinol); antihistamines (e.g., chlorpheniramine); cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol); corticosteroids; gastrointestinal agents (e.g., antacids); … |
| Aspirin | drug interactions | Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin); antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); … |
| Atenolol | drug interactions | … hydrochloride); antigout (e.g., allopurinol); antihistamines (e.g., chlorpheniramine); cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol); corticosteroids; gastrointestinal agents (e.g., antacids); hypoglycemics; sedatives and tranquilizers (e.g., diazepam). |
| Chlorpheniramine | drug interactions | … phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); antigout (e.g., allopurinol); antihistamines (e.g., chlorpheniramine); cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol); corticosteroids; gastrointestinal agents (e.g., antacids); hypoglycemics; … |
| Codeine | drug interactions | Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin); antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); … |
| Diazepam | drug interactions | … corticosteroids; gastrointestinal agents (e.g., antacids); hypoglycemics; sedatives and tranquilizers (e.g., diazepam). |
| Erythromycin | drug interactions | Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin); antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); … |
| Hydrochlorothiazide | drug interactions | … antigout (e.g., allopurinol); antihistamines (e.g., chlorpheniramine); cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol); corticosteroids; gastrointestinal agents (e.g., antacids); hypoglycemics; sedatives and tranquilizers (e.g., diazepam). |
| Ibuprofen | drug interactions | Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin); antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); … |
| Indomethacin | drug interactions | Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin); antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); … |
| Phenylephrine | drug interactions | … antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); anticholinergic/sympathomimetics (e.g., phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); antigout (e.g., allopurinol); antihistamines (e.g., chlorpheniramine); … |
| Propranolol | drug interactions | … antihistamines (e.g., chlorpheniramine); cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol); corticosteroids; gastrointestinal agents (e.g., antacids); hypoglycemics; sedatives and tranquilizers (e.g., diazepam). |
| Pseudoephedrine | drug interactions | … sulfamethoxazole); anticholinergic/sympathomimetics (e.g., phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); antigout (e.g., allopurinol); antihistamines (e.g., chlorpheniramine); cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol); … |
Every other medicine the terazosin label names
| Medicine named | Section | What the label says |
|---|---|---|
| Trimethoprim | drug interactions | … codeine, ibuprofen, indomethacin); antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); anticholinergic/sympathomimetics (e.g., phenylephrine hydrochloride, phenylpropanolamine … |
| Verapamil | drug interactions | DRUG INTERACTIONS Co-administration of verapamil with terazosin increases the systemic exposure of terazosin [see Clinical Pharmacology (12.3)], which may increase the risk of hypotenstion. |
Other labels that name terazosin
Source: FDA drug label (Terazosin), Jubilant Cadista Pharmaceuticals Inc., effective May 5, 2026 (SPL set 43e92495-2cf2-46dd-a80c-f0c3c88c7b73), via openFDA; the full label on DailyMed
What do FAERS reports show for terazosin?
The FDA Adverse Event Reporting System holds 8,843 reports that list terazosin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 951 are coded as a death and 3,213 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as terazosin?
9 other medicines are given the same way (oral) and in the same FDA class as terazosin or labeled mainly for the same use (enlarged prostate (bph)), the same class first. Enlarged prostate (BPH) lists all 8 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Carvedilol | High blood pressure | 41 labelers | $0.0179 per tablet 6.25 mg tablet | No current entry |
| Doxazosin | High blood pressure, Enlarged prostate (BPH) | 29 labelers | $0.0752 per tablet 1 mg tablet | No current entry |
| Prazosin | High blood pressure | 33 labelers | $0.0842 per capsule 1 mg capsule | A presentation being discontinued |
| Tamsulosin | Enlarged prostate (BPH) | 37 labelers | $0.05 per capsule 0.4 mg capsule | No current entry |
| Silodosin | Enlarged prostate (BPH) | 13 labelers | $0.319 per capsule 8 mg capsule | No current entry |
| Alfuzosin | Enlarged prostate (BPH) | 10 labelers | $0.105 per tablet 10 mg tablet | No current entry |
| Phenoxybenzamine | High blood pressure | 5 labelers | n/a | A presentation being discontinued |
| Finasteride | Enlarged prostate (BPH) | 30 labelers | $0.0688 per tablet 5 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does terazosin compare with medicines for the same use?
6 side-by-side pages set terazosin beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to terazosin
- 9 medicines for the same use
- Other alpha blockers
- the pharmacologic class, with prices and generics
- Terazosin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other